|View printer-friendly version|
|New Data Highlighting CytomX’s Probody Platform and EGFR Probody Drug Conjugate to be Presented at the AACR Annual Meeting 2013|
SAN FRANCISCO – April 3, 2013 – CytomX Therapeutics, Inc., a biotechnology company developing a new generation of highly targeted antibody therapeutics, today announced that data highlighting the company’s Probody™ Platform and EGFR Probody™ Drug Conjugate will be presented at this year’s American Association for Cancer Research (AACR) Annual Meeting 2013, being held April 6-10, 2013 at the Walter E. Washington Convention Center in Washington, D.C.
“As we continue to make rapid advances with our proprietary Probody Platform, we are excited to share new data on our EGFR Probody Drug Conjugate Program with our peers at AACR,” said Sean McCarthy, D. Phil., chief executive officer of CytomX. “In preclinical models, our lead EGFR Probody candidate has demonstrated localized anti-tumor activity within the disease microenvironment and avoids the significant dermatological toxicity that is a hallmark of currently approved treatments targeting EGFR. This unique profile serves as a launch pad to develop a highly targeted Probody Drug Conjugate against this clinically validated target, potentially opening up a new treatment option for several tumor types.”
Luc Desnoyers, Ph.D., director of cell biology at CytomX, will deliver an oral presentation titled “Development of a Proteolytically Activatable EGFR Probody for Cancer Therapy” during the “Back to the Future” mini-symposium on Tuesday, April 9, 2013 at 3:05 p.m. EST. The session will be held in Room 151.